2-(tert-Butyl-dimethyl-silanyloxy)-6-chloro-3-(2-fluoro-phenyliminomethyleneamino)-N,N-dimethyl-benzenesulfonamide | 364363-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(tert-Butyl-dimethyl-silanyloxy)-6-chloro-3-(2-fluoro-phenyliminomethyleneamino)-N,N-dimethyl-benzenesulfonamide
• 英文别名: N-(2-Fluorophenyl)-N'-[4-chloro-2-tert-butyldimethylsilyloxy-3-(N'',N''-dimethylaminosulfonyl)phenyl] carbodiimide
• CAS: 364363-44-0
• 化学式: C₂₁H₂₇ClFN₃O₃SSi
• 分子量: 484.067
• InChiKey: UXODHUAHBIKOJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.25
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  79.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(tert-Butyl-dimethyl-silanyloxy)-6-chloro-3-(2-fluoro-phenyliminomethyleneamino)-N,N-dimethyl-benzenesulfonamide 在 N,N-二异丙基乙胺 、 cesium fluoride 作用下， 以 甲醇 为溶剂， 生成 6-chloro-3-({(cyanoimino)[(2-fluorophenyl)amino]methyl}amino)-2-hydroxy-N,N-dimethylbenzenesulfonamide
  参考文献：
  名称：

  N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors

  摘要：

  A series of N-(2-hydroxy-3-sulfonamidobenzene)-N'-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to > 200-fold. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.042
• 作为产物：
  描述：

  2-叔丁基-6-氯苯并噁唑-7-磺酰氯 在 咪唑 、 硫酸 、 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(tert-Butyl-dimethyl-silanyloxy)-6-chloro-3-(2-fluoro-phenyliminomethyleneamino)-N,N-dimethyl-benzenesulfonamide
  参考文献：
  名称：

  N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors

  摘要：

  A series of N-(2-hydroxy-3-sulfonamidobenzene)-N'-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to > 200-fold. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.042

文献信息

• Il-8 receptor anatagonists
  申请人：——

  公开号：US20030216375A1

  公开（公告）日：2003-11-20

  This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及式（I）的新化合物及其组合物，其在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中具有用处。
• IL-8 receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06680317B2

  公开（公告）日：2004-01-20

  This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及一种新型化合物（I）及其组合物，其在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中有用。
• N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors
  作者：Hong Nie、Katherine L. Widdowson、Michael R. Palovich、Wei Fu、John D. Elliott、Deborah L. Bryan、Miriam Burman、Dulcie B. Schmidt、James J. Foley、Henry M. Sarau、Jakob Busch-Petersen

  DOI：10.1016/j.bmcl.2006.08.042

  日期：2006.11

  A series of N-(2-hydroxy-3-sulfonamidobenzene)-N'-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to > 200-fold. (c) 2006 Elsevier Ltd. All rights reserved.